Halozyme Therapeutics (HALO) Long-Term Deferred Tax (2021 - 2025)

Halozyme Therapeutics (HALO) has 5 years of Long-Term Deferred Tax data on file, last reported at $20.2 million in Q2 2025.

• On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $20.2 million in Q2 2025; TTM through Jun 2025 was $20.2 million, a N/A change from a year earlier, with the FY2024 full-year figure at $3.9 million, down 12.11% from the prior year.
• Long-Term Deferred Tax for Q2 2025 stood at $20.2 million, up from $5.2 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for HALO reached as high as $155.4 million in Q4 2021 and fell as low as $616000.0 in Q1 2024.
• Historically, Long-Term Deferred Tax has averaged $49.3 million across 5 years, with a median of $22.1 million in 2023.
• Across the five-year window, Long-Term Deferred Tax sank 98.27% in 2024 and jumped 742.53% in 2025, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $155.4 million in 2021, then plunged by 71.42% to $44.4 million in 2022, then sank by 90.13% to $4.4 million in 2023, then dropped by 12.11% to $3.9 million in 2024, then jumped by 424.2% to $20.2 million in 2025.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $20.2 million in Q2 2025, $5.2 million in Q1 2025, and $3.9 million in Q4 2024.